Enliven director sells 10,000 shares for $345,000
Enliven Therapeutics Director Lori Anne Kunkel sold 10,000 shares of common stock for a total consideration of approximately $345,000 on June 5, 2026.
The transaction was executed at a weighted average price of $34.54, with the stock closing at $34.71 on the transaction date.
The sale represented 16% of Kunkel’s direct common stock holdings, reducing her stake from 61,884 to 51,884 shares.
The transaction was completed under a pre-arranged plan adopted on March 6, 2026, with the stock subsequently appreciating to $50.